文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

调节性 T 细胞与三阴性乳腺癌的肿瘤免疫微环境和免疫治疗反应有关。

Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.

机构信息

Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.

Graduate School, Tianjin Medical University, Tianjin, China.

出版信息

Front Immunol. 2023 Sep 12;14:1263537. doi: 10.3389/fimmu.2023.1263537. eCollection 2023.


DOI:10.3389/fimmu.2023.1263537
PMID:37767092
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10521732/
Abstract

INTRODUCTION: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with a high risk of distant metastasis, an extremely poor prognosis, and a high risk of death. Regulatory T cells (Tregs) contribute to the formation of a tumor immunosuppressive microenvironment, which plays an important role in the progression and treatment resistance of TNBC. METHODS: A public single-cell sequencing dataset demonstrated increased infiltration of Tregs in TNBC tissues relative to normal breast tissue. Weighted gene co-expression network analysis was used to identify Treg infiltration-related modules for METABRIC TNBC samples. Subsequently, we obtained two Treg infiltration-associated clusters of TNBC by applying consensus clustering and further constructed a prognostic model based on this Treg infiltration-associated gene module. The ability of the selected gene in the prognostic model, thymidine kinase-1 (TK1), to promote the progression of TNBC was evaluated . RESULTS: We concluded that two Treg infiltration-associated clusters had different prognoses and sensitivities to drugs commonly used in breast cancer treatment, and multi-omics analysis revealed that the two clusters had different copy number variations of key tumor progression genes. The 7-gene risk score based on TNBC Treg infiltration was a reliable prognostic indicator both in the training and validation cohorts. Moreover, patients with TNBC with high Treg infiltration-related scores lacked the activation of immune activation pathways and exhibited resistance to anti-PD1 immunotherapy. Knocking down TK1 led to impaired proliferation, migration, and invasion of TNBC cells . In addition, specimens from patients with TNBC with high TK1 expression showed significantly higher Treg infiltration in tumors. Results of spatial transcriptome analysis showed that TK1 positive cells mainly localize in tumor area, and Treg cell infiltration in TNBC tissues was associated with high expression of TK1. Pan-cancer analysis also demonstrated that TK1 is associated with poor prognosis and activation of proliferation pathways in multiple cancers. DISCUSSION: We established a prognostic model related to Treg infiltration and this model can be used to establish a clinically relevant classification of TNBC progression. Additionally, our work revealed the underestimable potential of TK1 as a tumor biomarker and immunotherapeutic target.

摘要

简介:三阴性乳腺癌(TNBC)是乳腺癌中侵袭性最强的亚型,具有远处转移风险高、预后极差和死亡风险高的特点。调节性 T 细胞(Tregs)有助于形成肿瘤免疫抑制微环境,在 TNBC 的进展和治疗耐药中发挥重要作用。

方法:公共单细胞测序数据集表明,TNBC 组织中 Tregs 的浸润明显高于正常乳腺组织。采用加权基因共表达网络分析鉴定 METABRIC TNBC 样本中与 Treg 浸润相关的模块。随后,我们通过共识聚类获得了两个 TNBC 的 Treg 浸润相关簇,并进一步构建了基于该 Treg 浸润相关基因模块的预后模型。评估了所选基因(胸苷激酶-1(TK1))在促进 TNBC 进展方面的能力。

结果:我们得出结论,两个 Treg 浸润相关簇具有不同的预后和对乳腺癌治疗常用药物的敏感性,多组学分析表明,这两个簇具有不同的关键肿瘤进展基因的拷贝数变异。基于 TNBC Treg 浸润的 7 基因风险评分在训练和验证队列中都是可靠的预后指标。此外,高 Treg 浸润相关评分的 TNBC 患者缺乏免疫激活途径的激活,并且对抗 PD1 免疫治疗有耐药性。敲低 TK1 导致 TNBC 细胞增殖、迁移和侵袭受损。此外,高 TK1 表达的 TNBC 患者标本中肿瘤内 Treg 浸润明显更高。空间转录组分析结果表明,TK1 阳性细胞主要定位于肿瘤区域,TNBC 组织中 Treg 细胞浸润与 TK1 的高表达相关。泛癌分析也表明,TK1 与多种癌症的不良预后和增殖途径的激活相关。

讨论:我们建立了一个与 Treg 浸润相关的预后模型,该模型可用于建立 TNBC 进展的临床相关分类。此外,我们的工作揭示了 TK1 作为肿瘤标志物和免疫治疗靶点的被低估的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/16e78bc0446b/fimmu-14-1263537-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/07380c25e6cd/fimmu-14-1263537-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/ae3930f2315f/fimmu-14-1263537-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/b74fd3ca711b/fimmu-14-1263537-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/08cc18d68878/fimmu-14-1263537-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/abd67324635d/fimmu-14-1263537-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/6436a9a08f68/fimmu-14-1263537-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/f422028d0026/fimmu-14-1263537-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/d18535be71b3/fimmu-14-1263537-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/a3b7849be4b9/fimmu-14-1263537-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/16e78bc0446b/fimmu-14-1263537-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/07380c25e6cd/fimmu-14-1263537-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/ae3930f2315f/fimmu-14-1263537-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/b74fd3ca711b/fimmu-14-1263537-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/08cc18d68878/fimmu-14-1263537-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/abd67324635d/fimmu-14-1263537-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/6436a9a08f68/fimmu-14-1263537-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/f422028d0026/fimmu-14-1263537-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/d18535be71b3/fimmu-14-1263537-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/a3b7849be4b9/fimmu-14-1263537-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d419/10521732/16e78bc0446b/fimmu-14-1263537-g010.jpg

相似文献

[1]
Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.

Front Immunol. 2023

[2]
3D Collagen Fiber Concentration Regulates Treg Cell Infiltration in Triple Negative Breast Cancer.

Front Immunol. 2022

[3]
Research and experimental verification on the mechanisms of cellular senescence in triple-negative breast cancer.

PeerJ. 2024-2-29

[4]
A novel fatty-acid metabolism-based classification for triple negative breast cancer.

Aging (Albany NY). 2023-2-25

[5]
Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.

Cancer Rep (Hoboken). 2024-3

[6]
Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy.

Front Public Health. 2022

[7]
Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer.

Comput Biol Med. 2023-7

[8]
A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.

Clin Exp Med. 2023-11

[9]
Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.

Breast Cancer Res. 2021-2-18

[10]
The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer.

Cancer Biol Ther. 2024-12-31

引用本文的文献

[1]
Serum from patients with oral squamous cell carcinoma remodels the tumor immune escape ecological niche by promoting regulatory T‑cell differentiation and T‑cell exhaustion.

Oncol Rep. 2025-11

[2]
An immunotherapy guide constructed by cGAS-STING signature for breast cancer and the biofunction validation of the pivotal gene HOXC13 via experiments.

Front Immunol. 2025-8-8

[3]
Omics Integration Uncovers Mechanisms Associated with HIV Viral Load and Potential Therapeutic Insights.

medRxiv. 2025-7-30

[4]
The prognostic value of immunoscore in the early-onset colorectal cancer.

BMC Gastroenterol. 2025-7-10

[5]
Cancer Immunotherapy Based on the Bidirectional Reprogramming of the Tumor Microenvironment by a "Brakes Off/ Step on the Accelerator" Core-Shell Manganese Phosphate/siPD-L1 Modulator.

Exploration (Beijing). 2025-2-9

[6]
Multi-omics analysis untangles the crosstalk between intratumor microbiome, lactic acid metabolism and immune status in lung squamous cell carcinoma.

Front Immunol. 2025-6-11

[7]
Immune evasion and resistance in breast cancer.

Am J Cancer Res. 2025-4-15

[8]
Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges.

Vaccines (Basel). 2025-3-24

[9]
Leveraging Diverse Cell-Death Patterns to Decipher the Interactive Relation of Unfavorable Outcome and Tumor Microenvironment in Breast Cancer.

Bioengineering (Basel). 2025-4-15

[10]
Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy.

J Exp Clin Cancer Res. 2025-4-25

本文引用的文献

[1]
A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo.

Sci Adv. 2023-5-5

[2]
Model for predicting immunotherapy based on M2 macrophage infiltration in TNBC.

Front Immunol. 2023

[3]
Multi-Omics Integration Analysis of TK1 in Glioma: A Potential Biomarker for Predictive, Preventive, and Personalized Medical Approaches.

Brain Sci. 2023-1-30

[4]
Dissecting the role of cancer-associated fibroblast-derived biglycan as a potential therapeutic target in immunotherapy resistance: A tumor bulk and single-cell transcriptomic study.

Clin Transl Med. 2023-2

[5]
Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery.

Int J Surg. 2022-11

[6]
Bioinformatics and network-based screening and discovery of potential molecular targets and small molecular drugs for breast cancer.

Front Pharmacol. 2022-9-20

[7]
Thymidine Kinase 1 Drives Skin Cutaneous Melanoma Malignant Progression and Metabolic Reprogramming.

Front Oncol. 2022-3-3

[8]
Regulatory T cells: Their role in triple-negative breast cancer progression and metastasis.

Cancer. 2022-3-15

[9]
MicroRNA-1246 Mediates Drug Resistance and Metastasis in Breast Cancer by Targeting NFE2L3.

Front Oncol. 2021-12-1

[10]
Immunohistochemistry for Thymidine Kinase-1 (TK1): A Potential Tool for the Prognostic Stratification of Breast Cancer Patients.

J Clin Med. 2021-11-19

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索